These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review. Patterson MF; Borish L; Kennedy JL J Asthma Allergy; 2015; 8():125-34. PubMed ID: 26604804 [TBL] [Abstract][Full Text] [Related]
51. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. Rosenwasser LJ; Rothenberg ME J Allergy Clin Immunol; 2010 Jun; 125(6):1245-6. PubMed ID: 20513522 [No Abstract] [Full Text] [Related]
52. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. Pelaia C; Calabrese C; Vatrella A; Busceti MT; Garofalo E; Lombardo N; Terracciano R; Pelaia G Biomed Res Int; 2018; 2018():4839230. PubMed ID: 29862274 [TBL] [Abstract][Full Text] [Related]
53. Monoclonal antibodies for the treatment of refractory asthma. Hambly N; Nair P Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927 [TBL] [Abstract][Full Text] [Related]
54. Reslizumab (Cinqair) for severe eosinophilic asthma. Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070 [No Abstract] [Full Text] [Related]
55. Reslizumab: First Global Approval. Markham A Drugs; 2016 May; 76(8):907-11. PubMed ID: 27125787 [TBL] [Abstract][Full Text] [Related]
56. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. Heinisch IV; Bizer C; Volgger W; Simon HU J Allergy Clin Immunol; 2001 Jul; 108(1):21-8. PubMed ID: 11447378 [TBL] [Abstract][Full Text] [Related]
57. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome. Schrezenmeier H; Thomé SD; Tewald F; Fleischer B; Raghavachar A Exp Hematol; 1993 Feb; 21(2):358-65. PubMed ID: 8425573 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma. Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985 [TBL] [Abstract][Full Text] [Related]
60. Anti-IL5 therapy for asthma and beyond. Mukherjee M; Sehmi R; Nair P World Allergy Organ J; 2014; 7(1):32. PubMed ID: 25709744 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]